Pacific Biosciences of California Inc当前公司基本面数据相对稳定,增长潜力较大。当前估值合理,在医疗设备与耗材行业排名112/207位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价2.25。中期看,股价处于上升通道。近一个月,市场表现非常差,基本面和技术面综合得分也较低。目前股价在压力位和支撑位之间,可以做区间波段操作。
Pacific Biosciences of California Inc评分
相关信息
行业排名
112 / 207
全市场排名
279 / 4563
所属行业
医疗设备与耗材
压力支撑
由于公司未披露,未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
10
位分析师
买入
评级
2.250
目标均价
-3.02%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议
Pacific Biosciences of California Inc亮点
亮点风险
Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
公司代码PACB
公司Pacific Biosciences of California Inc
CEOHenry (Christian O)
网址https://www.pacb.com/
常见问题
Pacific Biosciences of California Inc(PACB)的当前股价是多少?
Pacific Biosciences of California Inc(PACB)的当前股价是 1.770。
Pacific Biosciences of California Inc的股票代码是什么?
Pacific Biosciences of California Inc的股票代码是PACB。
Pacific Biosciences of California Inc股票的52周最高点是多少?
Pacific Biosciences of California Inc股票的52周最高点是2.725。
Pacific Biosciences of California Inc股票的52周最低点是多少?
Pacific Biosciences of California Inc股票的52周最低点是0.851。
Pacific Biosciences of California Inc的市值是多少?
Pacific Biosciences of California Inc的市值是534.28M。
Pacific Biosciences of California Inc的净利润是多少?
Pacific Biosciences of California Inc的净利润为-309.85M。
现在Pacific Biosciences of California Inc(PACB)的股票是买入、持有还是卖出?
根据分析师评级,Pacific Biosciences of California Inc(PACB)的总体评级为买入,目标价格为2.250。
Pacific Biosciences of California Inc(PACB)股票的每股收益(EPS TTM)是多少
Pacific Biosciences of California Inc(PACB)股票的每股收益(EPS TTM)是-1.670。